Assistant Professor at Erasmus Medical Center in The Netherlands, working on elucidating the molecular mechanisms of cancer progression, aiming to turn laboratory discoveries into personalized cancer therapies. I am interested in characterizing the mode of function of HER2, and its partner HER3, in the pathological state of HER2 overexpression, in order to define a mechanistic basis for the development of novel therapeutic agents for the treatment of HER2-amplified cancers.As a postdoc fellow at the University of California San Francisco, I revealed new paradigms in cell signaling and cancer resistance in breast and colorectal cancers(published in Nature Cancer, Cancer Research and Oncogene, among others). In 2019, I established my own research group at Erasmus MC supported by the Marie Skłodowska-Curie Actions Programme and the Dutch Research Council. Our aim is to uncover the impact of aberrant tumor glycosylation on the efficacy of targeted therapies integrating clinical data, co-culture 3D immune-cancer spheroids and high-content live-imaging. Specifically, my lab is currently deciphering the impact of altered glycosylation on the response to HER2-targeting agents in breast cancer, including a recent and promising therapeutic agent developed by AstraZeneca.My experience in the US and Europe has enabled me to establish fruitful collaborations with international experts and the pharmaceutical industry. I have also actively participated in numerous conferences and outreach activities, including fundraising events and science communication events. And I am also a lecturer of the Molecular Medicine Master program at Erasmus Medical Center.